RxDoctor Payments DataLook up a doctor →

Shannon Morgenstern, NP

Nurse Practitioner · Oro Valley, AZNPI 1164940557

Payments from drug & device makers

$70,674in general payments, 2019–2025

Across 531 payments — averaging $133.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Curonix LLC$37K
  • Medtronic$16K
  • International Rehabilitative Sciences, Inc$7K
  • Nevro Corp.$3K
  • Nalu Medical, Inc.$1K
  • Boston Scientific$1K
  • plus $5K from 33 others

What the payments were for

  • Consulting fees$26,53638%
  • Speaking & faculty fees$3,6755%
  • Travel & lodging$16,92524%
  • Food & beverage$16,73024%
  • Education$1530%
  • Other$6,6569%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$70,674 in reported general payments places this provider in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$148,759
Medicare patients
231
Services billed
4,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl96$76,963
Xtampza ErOxycodone Myristate30$16,066
LyricaPregabalin12$10,767
Buprenorphine36$10,682
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen410$9,048
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen203$6,317
Pregabalin149$3,104
Gabapentin299$2,676
Oxycodone Hcl126$2,120
Morphine Sulfate ErMorphine Sulfate66$1,957
Lidocaine33$1,955
Baclofen99$1,352
Acetaminophen-CodeineAcetaminophen With Codeine75$1,246
Tramadol Hcl210$1,198
Duloxetine Hcl72$1,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$706$93,029126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Oro Valley

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →